[HTML][HTML] Measurable residual disease testing in multiple myeloma following T-cell redirecting therapies
KG Shim, R Fonseca - Cancers, 2024 - mdpi.com
Simple Summary Multiple myeloma (MM) is a blood cancer which classically has a
prolonged course of remissions and relapses. Several new highly efficacious medications …
prolonged course of remissions and relapses. Several new highly efficacious medications …
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
LJ Costa, P Rodriguez-Otero - Advances in Therapy, 2024 - Springer
Immunotherapies have significantly improved outcomes in patients with multiple myeloma
yet maintaining a durable response in heavily pretreated patients remains challenging …
yet maintaining a durable response in heavily pretreated patients remains challenging …
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
K Nath, T Shekarkhand, D Nemirovsky… - Blood Cancer …, 2024 - nature.com
Abstract B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple
myeloma, but infections are emerging as a major challenge. In this retrospective, single …
myeloma, but infections are emerging as a major challenge. In this retrospective, single …
[HTML][HTML] Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma
A Lesokhin, K Nath, T Shekarkhand… - Research …, 2024 - ncbi.nlm.nih.gov
Abstract B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple
myeloma, but infections are emerging as a major challenge. In this retrospective, single …
myeloma, but infections are emerging as a major challenge. In this retrospective, single …
[PDF][PDF] Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review
Teclistamab (TEC) is the first B-cell maturation antigen-directed bispecific antibody
approved by the European Medicines Agency and Food and Drug Administration for triple …
approved by the European Medicines Agency and Food and Drug Administration for triple …
[引用][C] Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
LJCP Rodriguez-Otero - 2024